| pubmed-article:12826215 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12826215 | lifeskim:mentions | umls-concept:C0376387 | lld:lifeskim |
| pubmed-article:12826215 | lifeskim:mentions | umls-concept:C0018823 | lld:lifeskim |
| pubmed-article:12826215 | lifeskim:mentions | umls-concept:C0232804 | lld:lifeskim |
| pubmed-article:12826215 | lifeskim:mentions | umls-concept:C0010592 | lld:lifeskim |
| pubmed-article:12826215 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:12826215 | lifeskim:mentions | umls-concept:C0209368 | lld:lifeskim |
| pubmed-article:12826215 | lifeskim:mentions | umls-concept:C1707719 | lld:lifeskim |
| pubmed-article:12826215 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:12826215 | pubmed:dateCreated | 2003-6-26 | lld:pubmed |
| pubmed-article:12826215 | pubmed:abstractText | We evaluated cyclosporine (CSA) dose reduction and mycophenolate mofetil (MMF) treatment versus maintained CSA dosage and azathioprine (AZA) in HTX regarding renal function and safety from CSA nephrotoxicity (creatinine > 1.7 mg/dL). | lld:pubmed |
| pubmed-article:12826215 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12826215 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12826215 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12826215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12826215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12826215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12826215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12826215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12826215 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12826215 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:12826215 | pubmed:issn | 0041-1345 | lld:pubmed |
| pubmed-article:12826215 | pubmed:author | pubmed-author:TondiMM | lld:pubmed |
| pubmed-article:12826215 | pubmed:author | pubmed-author:DalichauHH | lld:pubmed |
| pubmed-article:12826215 | pubmed:author | pubmed-author:PieskeBB | lld:pubmed |
| pubmed-article:12826215 | pubmed:author | pubmed-author:ZenkerDD | lld:pubmed |
| pubmed-article:12826215 | pubmed:author | pubmed-author:AleksicII | lld:pubmed |
| pubmed-article:12826215 | pubmed:author | pubmed-author:BaryaleiMM | lld:pubmed |
| pubmed-article:12826215 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12826215 | pubmed:volume | 35 | lld:pubmed |
| pubmed-article:12826215 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12826215 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12826215 | pubmed:pagination | 1539-42 | lld:pubmed |
| pubmed-article:12826215 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:12826215 | pubmed:meshHeading | pubmed-meshheading:12826215... | lld:pubmed |
| pubmed-article:12826215 | pubmed:meshHeading | pubmed-meshheading:12826215... | lld:pubmed |
| pubmed-article:12826215 | pubmed:meshHeading | pubmed-meshheading:12826215... | lld:pubmed |
| pubmed-article:12826215 | pubmed:meshHeading | pubmed-meshheading:12826215... | lld:pubmed |
| pubmed-article:12826215 | pubmed:meshHeading | pubmed-meshheading:12826215... | lld:pubmed |
| pubmed-article:12826215 | pubmed:meshHeading | pubmed-meshheading:12826215... | lld:pubmed |
| pubmed-article:12826215 | pubmed:meshHeading | pubmed-meshheading:12826215... | lld:pubmed |
| pubmed-article:12826215 | pubmed:meshHeading | pubmed-meshheading:12826215... | lld:pubmed |
| pubmed-article:12826215 | pubmed:meshHeading | pubmed-meshheading:12826215... | lld:pubmed |
| pubmed-article:12826215 | pubmed:meshHeading | pubmed-meshheading:12826215... | lld:pubmed |
| pubmed-article:12826215 | pubmed:meshHeading | pubmed-meshheading:12826215... | lld:pubmed |
| pubmed-article:12826215 | pubmed:meshHeading | pubmed-meshheading:12826215... | lld:pubmed |
| pubmed-article:12826215 | pubmed:meshHeading | pubmed-meshheading:12826215... | lld:pubmed |
| pubmed-article:12826215 | pubmed:meshHeading | pubmed-meshheading:12826215... | lld:pubmed |
| pubmed-article:12826215 | pubmed:meshHeading | pubmed-meshheading:12826215... | lld:pubmed |
| pubmed-article:12826215 | pubmed:meshHeading | pubmed-meshheading:12826215... | lld:pubmed |
| pubmed-article:12826215 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12826215 | pubmed:articleTitle | Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine. | lld:pubmed |
| pubmed-article:12826215 | pubmed:affiliation | Department of Thoracic and Cardiovascular Surgery, Georg-August-University, Göttingen, Germany. | lld:pubmed |
| pubmed-article:12826215 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12826215 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12826215 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
